Quantitative sensory testing

From Wikipedia, the free encyclopedia
Quantitative sensory testing
A440 Tuning Fork.jpg
Tuning forks are used to determine vibration detection thresholds.
SpecialtyNeurology

Quantitative sensory testing (QST) is a panel of diagnostic tests used to assess somatosensory function, in the context of research and as a supplemental tool in the diagnosis of somatosensory disorders, including pain insensitivity, painless and painful neuropathy. The panel of tests examine a broad range of different sensations, including hot, cold, touch, vibration. It has both positive and negative tests (can test for increased or reduced sensitivity). QST reflects a formalisation of existing neurological tests into a standardised battery designed to detect subtle changes in sensory function.[1] Large datasets representing normal responses to sensory tests have been established to quantitate deviation from the mean and allow comparison with normal patients. It is thought that a detailed evaluation of somatosensory function may be useful in identifying subtypes of pain and as a potential tool to identify asymptomatic neuropathy,[2] which may represent up to 50% of total people with neuropathy (or loss of the nerve fibres). In clinical use, it is often combined with other tests such as clinical electrophysiology.[3] In research settings it is increasingly applied in combination with advanced imaging such as fMRI, epidermis "nerve" biopsies and microneurography to classify subtypes of painful disorders.[4]

Clinical recommendations[]

The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) have recommended the clinical use of QST in the diagnosis and evaluation of patients with small and large fibre neuropathy as well as screening for deficits of the somatosensory system (which may include deficits in the brain for instance). The group also recommend that the technique not be used in patients in litigation, or with severe learning or cognitive deficits as it is likely to be inaccurate due to its psychophysical basis. The recommendations are based on large trials suggesting inter-test reliability of the method.[5]

Testing battery[]

Standard parameters are evaluated using calibrated testing apparatus. The tests can be performed in multiple areas of the body; the areas are limited by the existing available normal sensory data. All of the tests are repeated several times.[1] A widely used set of parameters was proposed by the German Research Network on Neuropathic Pain. Subject values are compared to normal data to determine whether the subject has a deficit in any modality.

Test Abbreviation Brief Description Purpose
Mechanical Detection Threshold MDT Graded Von Frey filaments - that deliver increasing stimulus intensity are applied to the subject, the first stimulus to be perceived is recorded. Identify dysfunction in Aβ fibres
Vibration Detection Threshold VDT A tuning fork is placed on a bony prominence such as the elbow or knee, the subject reports when they can no longer detect vibration. Identify dysfunction in Aβ fibres
Cold Detection Threshold CDT A peltier device applies an increasingly cold stimulus, the subject reports when they can feel cold. Identify dysfunction of Aδ fibres
Paradoxical Heat Sensations PHS Alternating stimuli of hot and cold are applied, the subject is asked if they feel heat when a cold stimulus is applied during this procedure. Either the dysfunction of Aδ fibres or the disruption of central cold processing.
Warm Detection Threshold WDT A peltier device is used to warm and area of the body, the subject reports when they feel warmth. Detect changes warm detection. C fibres are thought to contribute but the relative contributions are disputed.
Wind-up Ratio WUR The subject is asked to compare the perceived stimulus intensity of a single pin prick to ten consecutive pin pricks. Detect abnormal amplification of pain stimuli.
Mechanical Pain Threshold MPT A custom pin stimulator is used, it delivers pins at increasing force, the subject is asked to report the first detection of sharpness. Identify dysfunction of Aδ fibres, and C-fibers
Mechanical Pain Sensitivity MPS The same stimulator is used, a force ~8X higher than the threshold is used and the subject is asked to rate their pain on a 100 point scale. Identify dysfunction of Aδ fibres, and C-fibers
Cold Pain Threshold CPT A peltier device applies an increasingly cold stimulus, the subject is asked to report when they feel pain. Identify dysfunction of Aδ fibres
Heat Pain Threshold HPT A peltier device applies an increasingly hot stimulus, the subject is asked to report when they feel pain. Identify dysfunction of C fibres
Pressure Pain Threshold PPT A pressure application device is used to apply graded pressure, the subject is asked to report the point at which they feel pain. Identify dysfunction of Aδ fibres, and C-fibers
Dynamic Mechanical Allodynia ALL/DMA Pain score is reported for a moving innocuous mechanical stimuli, such as a cotton tip. Identify presence of allodynia

Rationale[]

In addition to diagnostic confidence with neuropathy, additional reasons may encourage the use of QST.

Classification of neuropathic pain[]

It is thought that patients with neuropathic pain can be grouped into clusters based on their sensory profiles and that this may have a role in determining treatment.[6] After-the fact (or Post Hoc) analysis of the responders to treatments in clinical trials have suggested different clinical responses may cluster based on phenotype and preliminary clinical trials suggest some analgesics show a greater efficacy in patient subtypes.[6] The european medicines agency allow the classification of patients by QST in clinical trials. It is proposed that in cases where efficacy is only shown in one identified QST group, the drug will only be approved for use with those patients. Additionally, in Europe, QST is now allowed as a secondary outcome in clinical trials. [7]

Early disease identification[]

A damaged (or neuropathic) nerve
Progressive neuropathy can lead to irreversible damage, early identification of asymptomatic neuropathy may prevent loss of limb.

The early identification of neuropathy particularly in diabetic neuropathy may be useful to identify people with asymptomatic neuropathy. Asymptomatic neuropathy is a clinical concern because patients with untreated neuropathy may develop ulcers and damage due to a loss of protective sensation.[8]

Weaknesses[]

QST relies on psychophysical report of responses to stimuli. As a result it may be subject to patient biases. Nerve conduction studies may provide a more reliable metric in certain clinical situations.[3] However, nerve conduction studies poorly identify hypersensitivity, QST can identify both loss and gain of function.[9] Psychophysical tests are generally affected by other difficult to control factors, such as stress, the experience of the tester, the room the test is in, the novelty of the environment and the person's temperament. The test is time consuming and may take an hour to perform, and for monitoring require multiple visits.[3]

See also[]

  • Laser-evoked potential

References[]

  1. ^ a b Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, et al. (August 2006). "Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values". Pain. 123 (3): 231–43. doi:10.1016/j.pain.2006.01.041. PMID 16697110. S2CID 44333.
  2. ^ Devigili G, Rinaldo S, Lombardi R, Cazzato D, Marchi M, Salvi E, et al. (December 2019). "Diagnostic criteria for small fibre neuropathy in clinical practice and research". Brain. 142 (12): 3728–3736. doi:10.1093/brain/awz333. PMC 6906595. PMID 31665231.
  3. ^ a b c Mendell JR, Sahenk Z (March 2003). "Clinical practice. Painful sensory neuropathy". The New England Journal of Medicine. 348 (13): 1243–55. doi:10.1056/NEJMcp022282. PMID 12660389.
  4. ^ Bannister K, Sachau J, Baron R, Dickenson AH (January 2020). "Neuropathic Pain: Mechanism-Based Therapeutics". Annual Review of Pharmacology and Toxicology. 60: 257–274. doi:10.1146/annurev-pharmtox-010818-021524. PMID 31914896.
  5. ^ Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, et al. (September 2013). "Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus". Pain. 154 (9): 1807–19. doi:10.1016/j.pain.2013.05.047. PMID 23742795. S2CID 6585083.
  6. ^ a b Vollert J, Maier C, Attal N, Bennett DL, Bouhassira D, Enax-Krumova EK, et al. (August 2017). "Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations". Pain. 158 (8): 1446–1455. doi:10.1097/j.pain.0000000000000935. PMC 5515640. PMID 28595241.
  7. ^ Davis, Karen D.; Aghaeepour, Nima; Ahn, Andrew H.; Angst, Martin S.; Borsook, David; Brenton, Ashley; Burczynski, Michael E.; Crean, Christopher; Edwards, Robert; Gaudilliere, Brice; Hergenroeder, Georgene W. (2020-06-15). "Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities". Nature Reviews Neurology. 16 (7): 381–400. doi:10.1038/s41582-020-0362-2. ISSN 1759-4766. PMC 7326705. PMID 32541893.
  8. ^ Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. (January 2017). "Diabetic Neuropathy: A Position Statement by the American Diabetes Association". Diabetes Care. 40 (1): 136–154. doi:10.2337/dc16-2042. PMC 6977405. PMID 27999003.
  9. ^ Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. (February 2017). "Neuropathic pain". Nature Reviews. Disease Primers. 3: 17002. doi:10.1038/nrdp.2017.2. PMC 5371025. PMID 28205574.
Retrieved from ""